Disease · MONDO_0003233

essential tremor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. essential tremor. Diseases, record MONDO_0003233. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003233

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: essential tremor; Open Targets
Open Targets ID: MONDO_0003233; Open Targets
Other names: Essential tremor (finding), Kinetic tremor, benign essential tremor, benign essential tremor (disorder) [Ambiguous]; Open Targets
Disease Ontology: DOID:4990; Disease Ontology
MeSH: D020329; MeSH
Orphanet: ORPHA:862; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 34 drugs, from ClinicalTrials.gov; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ULIXACALTAMIDE	CHEMBL3934636	Small molecule	Phase 3	ClinicalTrials.gov	4	3	3	Drugs and targets
PRAMIPEXOLE	CHEMBL301265	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OCTANOL	CHEMBL26215	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 2	ClinicalTrials.gov	3	3	2	Drugs and targets
T-2000	CHEMBL4297439	Small molecule	Phase 2	ClinicalTrials.gov	3	3	2	Drugs and targets
SUVECALTAMIDE	CHEMBL1684950	Small molecule	Phase 2	ClinicalTrials.gov	3	2	2	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
INCOBOTULINUMTOXINA	CHEMBL2108035		Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ZONISAMIDE	CHEMBL750	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets82

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	7	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 82

See all 82 targets

Trials40

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05122650	A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)	Phase 2	420	2025-07-24	Essential Tremor	SUVECALTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT03101241	A Phase 2 RCT Study of CX-8998 for Essential Tremor	Phase 2	95	2021-10-22	Essential Tremor	SUVECALTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02427646	Kinematic-guided BoNT-A Treatment for ET and PD Tremor	Phase 2	54	2019-08-20	Tremor	BOTULINUM TOXIN TYPE A, INCOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT02978781	A Study to Evaluate SAGE-217 in Participants With Essential Tremor	Phase 2	34	2021-02-17	Essential Tremor	ZURANOLONE	Its record names the disease	ClinicalTrials.gov
NCT02207946	Botulinum Toxin A to Treat Arm Tremor	Phase 2	30	2021-02-18	Essential Tremor of the Upper Limbs	INCOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00848172	Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor	Phase 1/2	29	2012-12-27	Essential Tremor	OCTANOIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02277106	Evaluate SAGE-547 in Participants With Essential Tremor	Phase 2	25	2022-06-29	Essential Tremor	BREXANOLONE	Its record names the disease	ClinicalTrials.gov
NCT03688685	A Clinical Study to Evaluate CAD-1883 in Essential Tremor	Phase 2	25	2021-07-09	Essential Tremor	RIMTUZALCAP	Its record names the disease	ClinicalTrials.gov
NCT05021978	A Clinical Trial of PRAX-944 in Participants With Essential Tremor	Phase 2	24	2024-03-01	Essential Tremor	ULIXACALTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00102596	Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor	Phase 2	21	2012-02-01	Essential Tremor	OCTANOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 40

See all 40 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CX-8998 vs Placebo: deaths from any cause	0 of 48	0 of 47	95	NCT03101241	Trial comparisons
CX-8998 vs Placebo: serious adverse events	1 of 48	0 of 47	95	NCT03101241	Trial comparisons
Essential Tremor Treatment vs Parkinson Disease Tremor Treatment: deaths from any cause	0 of 24	0 of 28	52	NCT02427646	Trial comparisons
Essential Tremor Treatment vs Parkinson Disease Tremor Treatment: serious adverse events	0 of 24	0 of 28	52	NCT02427646	Trial comparisons
Pregabalin vs Placebo: serious adverse events	0 of 20	0 of 18	38	NCT00646451	Trial comparisons
Octanoic Acid vs Placebo: deaths from any cause	0 of 17	0 of 17	34	NCT01864525	Trial comparisons
Octanoic Acid vs Placebo: serious adverse events	0 of 17	0 of 17	34	NCT01864525	Trial comparisons
IncobotulinumtoxinA 30 to 200 U vs Placebo: deaths from any cause	0 of 19	0 of 11	30	NCT02207946	Trial comparisons
IncobotulinumtoxinA 30 to 200 U vs Placebo: serious adverse events	0 of 19	2 of 11	30	NCT02207946	Trial comparisons
Flexors Alone vs Flexors Plus Extensors: deaths from any cause	0 of 10	0 of 9	19	NCT02909907	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33419261	RESULT	1	PubMed
23408867	RESULT	1	PubMed
22454323	RESULT	1	PubMed
21594724	RESULT	2	PubMed
15210907	RESULT	1	PubMed
14718713	RESULT	1	PubMed
31244760	DERIVED	1	PubMed
27101283	DERIVED	1	PubMed
26927672	DERIVED	1	PubMed
20201005	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003233

GET https://conductscience.org/api/diseases/v1/MONDO_0003233/drugs?page=2

API reference For AI assistants